Abstract:Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. However, how to accurately evaluate the risk of breast cancer recurrence and metastasis after adjuvant TAM therapy is still a major concern. In recent years, many studies have shown that the clinical outcomes of TAM-treated breast cancer patients are influenced by the activity of some cytochrome P450 (CYP) enzymes that catalyze the formation of active TAM metabolites like endoxifen and 4-hydroxytamoxifen. In this study, we aimed to first develop and validate an algorithm combining polymorphisms in CYP genes and clinicopathological signatures to identify a subpopulation of breast cancer patients who might benefit most from TAM adjuvant therapy and meanwhile evaluate major risk factors related to TAM resistance. Specifically, a total of 256 patients with invasive breast cancer who received adjuvant endocrine therapy were selected. The genotypes at 10 loci from three TAM metabolism-related CYP genes were detected by time-of-flight mass spectrometry and multiplex long PCR. Combining the 10 loci with nine clinicopathological characteristics, we obtained 19 important features whose association with cancer recurrence was assessed by importance score via random forests. After that, a logistic regression model was trained to calculate TAM risk-of-recurrence score (TAM RORs), which is adopted to assess a patient’s risk of recurrence after TAM treatment. The sensitivity and specificity of the model in an independent test cohort were 86.67% and 64.56%, respectively. This study showed that breast cancer patients with high TAM RORs were less sensitive to TAM treatment and manifested more invasive characteristics, whereas those with low TAM RORs were highly sensitive to TAM treatment, and their conditions were stable during the follow-up period. There were some risk factors that had a significant effect on the efficacy of TAM. They were tissue classification (tumor Grade < 2 vs . Grade ≥ 2, p = 2.2e−16), the number of lymph node metastases (Node-Negative vs . Node < 4, p = 5.3e−07; Node < 4 vs . Node ≥ 4, p = 0.003; Node-Negative vs . Node ≥ 4, p = 7.2e−15), and the expression levels of estrogen receptor (ER) and progesterone receptor (PR) (ER < 50% vs . ER ≥ 50%, p = 1.3e−12; PR < 50% vs . PR ≥ 50%, p = 2.6e−08). The really remarkable thing is that different genotypes of CYP2D6*10(C188T) show significant differences in prediction function ( CYP2D6*10 CC vs . TT , p < 0.019; CYP2D6*10 CT vs . TT , p < 0.037). There are more than 50% Chinese who have CYP2D6*10 mutation. So the genotype of CYP2D6*10(C188T) should be tested before TAM therapy.

Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

Hypomethylation Associated Enhanced Transcription of Trefoil Factor-3 Mediates Tamoxifen-Stimulated Oncogenicity of ER+ Endometrial Carcinoma Cells

Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis

Pathology of endometrium treated with tamoxifen.

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Association of CYP2D6*10 (c.100c>t) Polymorphisms with Clinical Outcome of Breast Cancer after Tamoxifen Adjuvant Endocrine Therapy in Chinese Population.

Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics

The clinic-pathology of gynecological complications in 134 cases of breast cancer

Abstract 992: The impact of tamoxifen on autophagic and epigenetic regulation in endometrial cancer

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Tumor-Associated Macrophages Correlate with Progesterone Receptor Loss in Endometrial Endometrioid Adenocarcinoma

Tamoxifen Represses Mir-200 Micrornas and Promotes Epithelial-to-mesenchymal Transition by Up-Regulating C-Myc in Endometrial Carcinoma Cell Lines.

Pathological Analysis of 42 Patients with Tamoxifen Associated Endometrial Cancer

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen

Effect of tamoxifen on proliferation of human endometrial carcinoma cell line Ishikawa cells

Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings

Tumor-Associated Macrophages Are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells.

Alterations of Genetic Variants and Transcriptomic Features of Response to Tamoxifen in the Breast Cancer Cell Line